Search
CG Oncology Inc
CGONAdd to Watchlist
68.720USD
+2.990+4.55%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
6.05BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-24The current earnings forecast score of CG Oncology Inc is 8.25, ranking 146 out of 388 in the Biotechnology & Medical Research industry. The average price target is 68.50, with a high of 100.00 and a low of 55.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
89.846
Target Price
+47.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
CG Oncology Inc
CGON
16
Beigene Ltd
ONC
27
Ionis Pharmaceuticals Inc
IONS
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is CG Oncology Inc's expected revenue for the next quarter?
CG Oncology Inc's expected revenue is 334.23K.
What is CG Oncology Inc's price target?
Analysts forecast that CG Oncology Inc's price target is USD 68.50, with the highest forecast at USD 100.00 and the lowest forecast at USD 55.00.
How have CG Oncology IncCGON's recent earnings per share performed?
The market expectation was USD -0.71, while CG Oncology IncCGON's earnings per share (EPS) for the previous quarter was USD -0.52. EPS for the next quarter is expected at USD -0.66.
What is the analyst rating for CG Oncology Inc?
Based on the ratings of CG Oncology Inc's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
